8-K Announcements
6Material company update
Apr 1, 2026·SEC
Material company update
Mar 16, 2026·SEC
Material company update
Feb 3, 2026·SEC
Perspective Therapeutics, Inc.(CATX)Earnings, Financials & Key Ratios
CATX•AMEX
$3.82
$284M mkt cap·Price updated May 6, 2026
AboutPerspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.Show more
- Revenue$0-100.0%
- EBITDA$10M+126.2%
- Net Income-$79M-70.5%
- EPS (Diluted)-1.23-44.7%
- ROE-43.34%+39.5%
- ROIC5.2%+108.7%
- Debt/Equity0.01-58.8%
CATX Key Insights
Perspective Therapeutics, Inc. (CATX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 0.8x book value
✗Weaknesses
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Shares diluted 17.3% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
CATX Price & Volume
Perspective Therapeutics, Inc. (CATX) stock price & volume — 10-year historical chart
Loading chart...
CATX Growth Metrics
Perspective Therapeutics, Inc. (CATX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-74.35%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-92.54%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-49.38%
Return on Capital
10 Years-40.23%
5 Years-26.06%
3 Years-26.49%
Last Year5.16%
CATX Recent Earnings
Perspective Therapeutics, Inc. (CATX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 5/12 qtrs (42%)
Q2 2026Latest
Mar 16, 2026EPS
$0.51
Est $0.37
-37.8%
Revenue
$43,000
Est $232,478
-81.5%
Q4 2025
Nov 10, 2025EPS
$0.35
Est $0.33
-6.1%
Revenue
$209,000
Est $232,480
-10.1%
Q3 2025
Aug 13, 2025EPS
$0.30
Est $0.30
+0.0%
Revenue
$234,000
Est $174,600
+34.0%
Q2 2025
May 12, 2025EPS
$0.25
Est $0.28
+10.7%
Revenue
$342,000
Est $185,860
+84.0%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 16, 2026 | $0.51vs $0.37-37.8% | $43,000vs $232,478-81.5% |
| Q4 2025 | Nov 10, 2025 | $0.35vs $0.33-6.1% | $209,000vs $232,480-10.1% |
| Q3 2025 | Aug 13, 2025 | $0.30vs $0.30+0.0% | $234,000vs $174,600+34.0% |
| Q2 2025 | May 12, 2025 | $0.25vs $0.28+10.7% | $342,000vs $185,860+84.0% |
Based on last 12 quarters of dataView full earnings history →
CATX Peer Comparison
Perspective Therapeutics, Inc. (CATX) competitors in Imaging, radiation, and oncology devices — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 AGEN | 137.4M | 3.89 | -1144.12 | 10.37% | 0.1% | |||
 RNW | 1.34B | 5.45 | 47.45 | 19.36% | 9.23% | 8.42% | 5.59 | |
 LNTH | 5.61B | 86.15 | 25.26 | 0.5% | 15.15% | 20.58% | 0.00 | |
 NVX | 156.93M | 0.73 | -1.22 | -51.75% | -8.76% | -81.63% | 0.51 | |
 RVMD | 32.12B | 151.07 | -25.39 | -83.22% | 0.10 | |||
 DVAX | 1.82B | 15.50 | 77.50 | 19.36% | -13.13% | -8.13% | 0.43 | |
 NUVL | 6.92B | 104.26 | -26.53 | -45.12% | ||||
 NVO | 203.36B | 45.76 | 12.65 | 6.43% | 33.14% | 61.1% | 0.67 |
Compare CATX vs Peers
Perspective Therapeutics, Inc. (CATX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CATX Income Statement
Perspective Therapeutics, Inc. (CATX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 4.76M | 5.92M | 7.31M | 9.68M | 10.05M | 10.79M | 7.1M | 1.43M | 0 | 576K |
| Revenue Growth % | -0.17% | 24.41% | 23.48% | 32.35% | 3.85% | 7.38% | -34.19% | -79.81% | -100% | -74.35% |
| Cost of Goods Sold | 3.92M | 4.08M | 4.27M | 4.56M | 4.93M | 6.18M | 5.47M | 0 | 0 | 1.44M |
| COGS % of Revenue | 82.4% | 68.9% | 58.34% | 47.07% | 49.06% | 57.24% | 77% | - | - | - |
| Gross Profit | 838K▲ 0% | 1.84M▲ 119.8% | 3.05M▲ 65.4% | 5.12M▲ 68.2% | 5.12M▼ 0.1% | 4.62M▼ 9.9% | 1.63M▼ 64.6% | 1.43M▼ 12.2% | 0▼ 100.0% | -865K▲ 0% |
| Gross Margin % | 17.6% | 31.1% | 41.66% | 52.93% | 50.94% | 42.76% | 23% | 100% | - | -150.17% |
| Gross Profit Growth % | 548.84% | 119.81% | 65.42% | 68.17% | -0.06% | -9.86% | -64.6% | -12.24% | -100% | - |
| Operating Expenses | 7.14M | 8.57M | 8.32M | 8.6M | 8.56M | 12.01M | 17.43M | 42.38M | 92.34M | 107.32M |
| OpEx % of Revenue | 150.07% | 144.71% | 113.82% | 88.84% | 85.13% | 111.23% | 245.3% | 2955.02% | - | - |
| Selling, General & Admin | 6.23M | 6.83M | 6.85M | 7.55M | 7.13M | 9.43M | 14.21M | 21.06M | 26.61M | 31.31M |
| SG&A % of Revenue | 130.81% | 115.23% | 93.67% | 77.96% | 70.93% | 87.31% | 200.08% | 1468.9% | - | - |
| Research & Development | 965K | 1.75M | 1.47M | 1.13M | 1.43M | 2.58M | 2.6M | 21.31M | 41.64M | 51.42M |
| R&D % of Revenue | 20.27% | 29.48% | 20.15% | 11.63% | 14.19% | 23.92% | 36.63% | 1486.12% | - | - |
| Other Operating Expenses | -48K | 0 | 2K | -73K | 0 | 0 | 0 | 0 | 24.09M | 658K |
| Operating Income | -6.31M▲ 0% | -6.73M▼ 6.7% | -5.28M▲ 21.6% | -3.48M▲ 34.1% | -3.44M▲ 1.1% | -7.39M▼ 115.0% | -15.18M▼ 105.4% | -40.94M▼ 169.7% | 10.46M▲ 125.5% | -106.34M▲ 0% |
| Operating Margin % | -132.47% | -113.61% | -72.16% | -35.91% | -34.19% | -68.47% | -213.71% | -2855.02% | - | -18462.67% |
| Operating Income Growth % | -24.1% | -6.69% | 21.56% | 34.14% | 1.12% | -115.04% | -105.41% | -169.67% | 125.55% | - |
| EBITDA | -6.24M | -6.65M | -5.3M | -3.33M | -3.43M | -7.14M | -14.84M | -39.96M | 10.46M | -103.51M |
| EBITDA Margin % | -131.04% | -112.26% | -72.49% | -34.39% | -34.1% | -66.17% | -208.87% | -2786.61% | - | -17971.18% |
| EBITDA Growth % | -35.3% | -6.57% | 20.26% | 37.21% | -2.97% | -108.37% | -107.73% | -169.31% | 126.17% | -134.35% |
| D&A (Non-Cash Add-back) | 68K | 80K | -24K | 147K | 9K | 248K | 344K | 981K | 0 | 2.83M |
| EBIT | -6.31M | -6.73M | -5.28M | 0 | -3.44M | 0 | -15.18M | -40.94M | -81.42M | -117.65M |
| Net Interest Income | 118K | 29K | 108K | 30K | 59K | 0 | 1.12M | 850K | 10.56M | 11.13M |
| Interest Income | 118K | 29K | 108K | 30K | 59K | 119K | 1.12M | 934K | 10.52M | 11.26M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 119K | 0 | 84K | -48K | 124K |
| Other Income/Expense | 27K | 29K | 134K | 30K | 50K | 119K | 512K | 835K | -91.83M | -11.43M |
| Pretax Income | -6.16M▲ 0% | -6.7M▼ 8.7% | -5.14M▲ 23.2% | -3.45M▲ 33.0% | -3.39M▲ 1.7% | -7.27M▼ 114.7% | -14.67M▼ 101.7% | -40.11M▼ 173.4% | -81.38M▼ 102.9% | -117.77M▲ 0% |
| Pretax Margin % | -129.43% | -113.12% | -70.33% | -35.6% | -33.69% | -67.36% | -206.5% | -2796.79% | - | -20446.53% |
| Income Tax | -145K | -29K | -294K | -177K | -199K | -119K | 0 | -2.65M | -2.1M | -4.19M |
| Effective Tax Rate % | 2.35% | 0.43% | 5.72% | 5.14% | 5.88% | 1.64% | 0% | 6.61% | 2.58% | 3.56% |
| Net Income | -6.16M▲ 0% | -6.7M▼ 8.7% | -4.85M▲ 27.6% | -3.27M▲ 32.6% | -3.19M▲ 2.5% | -7.15M▼ 124.4% | -14.67M▼ 105.1% | -46.51M▼ 217.0% | -79.28M▼ 70.5% | -113.64M▲ 0% |
| Net Margin % | -129.43% | -113.12% | -66.31% | -33.77% | -31.71% | -66.26% | -206.5% | -3243.24% | - | -19728.65% |
| Net Income Growth % | -30.81% | -8.73% | 27.61% | 32.6% | 2.48% | -124.37% | -105.09% | -217.03% | -70.46% | -92.54% |
| Net Income (Continuing) | - | - | -4.85M | -3.27M | -3.19M | -7.15M | -14.67M | -37.45M | -80.43M | -113.52M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -9.05M | -949K | -59K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.11▲ 0% | -0.12▼ 9.1% | -0.07▲ 39.8% | -0.05▲ 33.1% | -0.06▼ 20.0% | -0.13▼ 123.8% | -0.27▼ 107.7% | -0.85▼ 214.8% | -1.23▼ 44.7% | -1.61▲ 0% |
| EPS Growth % | -28.5% | -9.09% | 39.75% | 33.06% | -20.04% | -123.75% | -107.69% | -214.81% | -44.71% | -49.38% |
| EPS (Basic) | -0.11 | -0.12 | -0.07 | -0.05 | -0.06 | -0.13 | -0.27 | -0.85 | -1.23 | - |
| Diluted Shares Outstanding | 55.02M | 55.16M | 67.04M | 67.6M | 54.91M | 54.91M | 54.91M | 54.91M | 64.42M | 70.67M |
| Basic Shares Outstanding | 55.02M | 55.16M | 67.04M | 67.6M | 54.91M | 54.91M | 54.91M | 54.91M | 64.42M | 70.67M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
CATX Balance Sheet
Perspective Therapeutics, Inc. (CATX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 10.29M | 5.47M | 7.32M | 5.51M | 12.29M | 63.6M | 53.22M | 16.84M | 231.16M | 195.96M |
| Cash & Short-Term Investments | 8.97M | 3.42M | 5.33M | 2.39M | 9.59M | 60.35M | 43.76M | 9.24M | 226.92M | 191.58M |
| Cash Only | 5.93M | 2.6M | 5.33M | 2.39M | 9.59M | 60.35M | 20.99M | 9.24M | 61.58M | 28.85M |
| Short-Term Investments | 3.04M | 825K | 0 | 0 | 0 | 0 | 22.76M | 0 | 165.34M | 162.73M |
| Accounts Receivable | 726K | 1.19M | 1.15M | 2.04M | 1.74M | 1.65M | 1.36M | 1.18M | 116K | 225K |
| Days Sales Outstanding | 55.66 | 73.46 | 57.59 | 77.07 | 63.1 | 55.69 | 70.03 | 299.08 | - | 317.32 |
| Inventory | 323K | 516K | 530K | 645K | 665K | 1.07M | 1.41M | 0 | 0 | 0 |
| Days Inventory Outstanding | 30.05 | 46.15 | 45.34 | 51.67 | 49.21 | 63.09 | 94.02 | - | - | -86.56 |
| Other Current Assets | 271K | 335K | 305K | 426K | 301K | 535K | 6.69M | 5.35M | 4.13M | 4.16M |
| Total Non-Current Assets | 1.98M | 1.99M | 2.11M | 3.19M | 3.22M | 3.65M | 2.3M | 81.05M | 109.94M | 114.77M |
| Property, Plant & Equipment | 1.05M | 1.31M | 1.61M | 2.74M | 2.72M | 2.62M | 2.06M | 6.32M | 59.54M | 64.37M |
| Fixed Asset Turnover | 4.52x | 4.52x | 4.55x | 3.54x | 3.69x | 4.13x | 3.45x | 0.23x | - | 0.01x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 24.06M | 0 | 0 |
| Intangible Assets | 230K | 198K | 162K | 138K | 130K | 107K | 86K | 50.35M | 50M | 50M |
| Long-Term Investments | 0 | 0 | 181K | 181K | 0 | 0 | 150K | 133K | 0 | 322K |
| Other Non-Current Assets | 694K | 478K | 155K | 137K | 373K | 926K | -2.3M | 182K | 405K | 1.53M |
| Total Assets | 12.27M▲ 0% | 7.46M▼ 39.2% | 9.42M▲ 26.4% | 8.7M▼ 7.7% | 15.51M▲ 78.3% | 67.25M▲ 333.5% | 58.09M▼ 13.6% | 97.89M▲ 68.5% | 341.1M▲ 248.4% | 310.73M▲ 0% |
| Asset Turnover | 0.39x | 0.79x | 0.78x | 1.11x | 0.65x | 0.16x | 0.12x | 0.01x | - | 0.00x |
| Asset Growth % | -32.22% | -39.24% | 26.38% | -7.67% | 78.33% | 333.52% | -13.62% | 68.51% | 248.45% | 501.24% |
| Total Current Liabilities | 1.11M | 1.83M | 1.12M | 1.57M | 1.33M | 1.84M | 2.68M | 15.66M | 18.23M | 12.99M |
| Accounts Payable | 630K | 1.39M | 683K | 654K | 494K | 847K | 1.54M | 6.91M | 10.34M | 7.05M |
| Days Payables Outstanding | 58.62 | 124.41 | 58.42 | 52.39 | 36.56 | 50.03 | 102.83 | - | - | 3.04K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 49K | 52K | 54K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.4M | 2.8M |
| Other Current Liabilities | 138K | 175K | 142K | 204K | 218K | 259K | -406K | 4.73M | 5.48M | 5.04M |
| Current Ratio | 9.30x | 2.98x | 6.53x | 3.50x | 9.21x | 34.47x | 19.89x | 1.07x | 12.68x | 12.68x |
| Quick Ratio | 9.01x | 2.70x | 6.05x | 3.09x | 8.71x | 33.89x | 19.36x | 1.07x | 12.68x | 12.68x |
| Cash Conversion Cycle | 27.09 | -4.8 | 44.5 | 76.35 | 75.76 | 68.74 | 61.22 | - | - | -2.8K |
| Total Non-Current Liabilities | 561K | 590K | 621K | 1.4M | 1.41M | 1.02M | 0 | 7.05M | 32.2M | 32.05M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.68M | 1.63M | 1.6M |
| Capital Lease Obligations | 0 | 0 | 0 | 769K | 652K | 392K | 0 | 780K | 1.43M | 5.35M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.59M | 2.5M | 12.08M |
| Other Non-Current Liabilities | 561K | 590K | 621K | 632K | 753K | 624K | 0 | 0 | 55K | 517K |
| Total Liabilities | 1.67M | 2.42M | 1.74M | 2.98M | 2.74M | 2.86M | 3.45M | 22.71M | 50.43M | 45.03M |
| Total Debt | 0 | 0 | 0 | 1M | 897K | 652K | 0 | 2.55M | 4.06M | 3.57M |
| Net Debt | -5.93M | -2.6M | -5.33M | -1.39M | -8.69M | -59.7M | -20.99M | -6.69M | -57.52M | -25.28M |
| Debt / Equity | - | - | - | 0.18x | 0.07x | 0.01x | - | 0.03x | 0.01x | 0.01x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | 0.39x | -0.03x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | -5.50x | -5.50x |
| Interest Coverage | - | - | - | - | - | -62.11x | - | -487.39x | - | -948.77x |
| Total Equity | 10.6M▲ 0% | 5.03M▼ 52.6% | 7.68M▲ 52.7% | 5.72M▼ 25.5% | 12.77M▲ 123.2% | 64.39M▲ 404.1% | 54.64M▼ 15.1% | 75.18M▲ 37.6% | 290.67M▲ 286.6% | 265.69M▲ 0% |
| Equity Growth % | -35.36% | -52.56% | 52.68% | -25.48% | 123.19% | 404.12% | -15.14% | 37.58% | 286.63% | 520.93% |
| Book Value per Share | 0.19 | 0.09 | 0.11 | 0.08 | 0.23 | 1.17 | 1.00 | 1.37 | 4.51 | 3.76 |
| Total Shareholders' Equity | 10.6M | 5.03M | 7.68M | 5.72M | 12.77M | 64.39M | 54.64M | 75.18M | 290.67M | 265.69M |
| Common Stock | 55K | 56K | 67K | 69K | 87K | 142K | 142K | 282K | 70K | 74K |
| Retained Earnings | -72.6M | -79.35M | -84.49M | -87.94M | -89.52M | -95.17M | -105.93M | -152.44M | -231.72M | -271.38M |
| Treasury Stock | - | - | - | - | - | - | - | 0 | 0 | 0 |
| Accumulated OCI | -7.59M | -7.67M | 0 | 0 | 0 | 0 | 0 | 0 | -51K | 3K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CATX Cash Flow Statement
Perspective Therapeutics, Inc. (CATX) cash flow — operating, investing & free cash flow history
| Line item | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -5.71M | -5.71M | -5.05M | -3.64M | -2.84M | -7.71M | -12.17M | -36.91M | -18.29M | -18.29M |
| Operating CF Margin % | -119.97% | -96.44% | -69.03% | -37.61% | -28.22% | -71.42% | -171.34% | -2574.13% | - | - |
| Operating CF Growth % | -47.06% | 0% | 11.61% | 27.89% | 22.08% | -171.77% | -57.87% | -203.26% | 50.44% | -373.28% |
| Net Income | -6.16M | -6.7M | -5.14M | -3.45M | -3.39M | -7.27M | -14.67M | -46.51M | -79.28M | -113.64M |
| Depreciation & Amortization | 68K | 80K | 136K | 147K | 149K | 248K | 344K | 946K | 2.31M | 3.31M |
| Stock-Based Compensation | 372K | 607K | 420K | 495K | 386K | 1.09M | 1.34M | 3.74M | 5.39M | 10.61M |
| Deferred Taxes | -33K | 0 | -24K | 0 | 10K | 0 | -1.68M | -2.65M | -2.1M | -9.95M |
| Other Non-Cash Items | 26K | 79K | 81K | -2K | 72K | 77K | 472K | 5.27M | 55.39M | 5.31M |
| Working Capital Changes | 17K | 222K | -518K | -835K | -67K | -1.85M | 338K | 2.3M | 0 | -936K |
| Change in Receivables | -184K | -466K | 38K | -890K | 31K | 405K | 490K | -426K | 1.05M | 1.75M |
| Change in Inventory | 89K | 23K | 128K | -97K | -274K | -2.67M | -152K | 359K | 11K | -170K |
| Change in Payables | 18K | 761K | -708K | -29K | 76K | 236K | 0 | 1.58M | 1.89M | -5.79M |
| Cash from Investing | 1.51M | 1.86M | 401K | -287K | -410K | -284K | -57.68M | 24.37M | -218.93M | -174.32M |
| Capital Expenditures | -549K | -337K | -444K | -273K | -381K | -266K | -302K | -1.07M | -54.41M | -53.79M |
| CapEx % of Revenue | 11.53% | 5.69% | 6.07% | 2.82% | 3.79% | 2.46% | 4.25% | 74.76% | - | - |
| Acquisitions | 6K | 0 | 34K | 0 | 1K | 0 | 0 | 2.7M | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -124K | -18K | -14K | -14K | -30K | -18K | -57.38M | -18K | 78.99M | 227K |
| Cash from Financing | -9K | 521K | 7.37M | 994K | 64.68M | 56K | 56K | 785K | 289.38M | 20.19M |
| Debt Issued (Net) | - | - | - | - | - | - | - | -68K | 0 | -41K |
| Equity Issued (Net) | - | - | - | - | - | - | - | 364K | 0 | 0 |
| Dividends Paid | -11K | -11K | -11K | -11K | -9K | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 0 | 0 | 0 | 0 | 56K | 489K | 289.38M | 22.13M |
| Net Change in Cash | -4.21M▲ 0% | -3.33M▲ 20.8% | 2.73M▲ 181.8% | -2.93M▼ 207.6% | 61.44M▲ 2194.0% | -7.94M▼ 112.9% | 182K▲ 102.3% | -46.65M▼ 25733.0% | 52.16M▲ 211.8% | -188.35M▲ 0% |
| Free Cash Flow | -6.26M▲ 0% | -6.05M▲ 3.4% | -5.49M▲ 9.2% | -3.91M▲ 28.7% | -3.22M▲ 17.8% | -7.98M▼ 147.9% | -12.47M▼ 56.4% | -37.98M▼ 204.5% | -72.71M▼ 91.4% | -112.45M▲ 0% |
| FCF Margin % | -131.51% | -102.13% | -75.1% | -40.43% | -32.01% | -73.89% | -175.59% | -2648.88% | - | -19522.05% |
| FCF Growth % | -43.08% | 3.39% | 9.19% | 28.75% | 17.78% | -147.86% | -56.39% | -204.51% | -91.41% | -357.57% |
| FCF per Share | -0.11 | -0.11 | -0.08 | -0.06 | -0.06 | -0.15 | -0.23 | -0.69 | -1.13 | -1.13 |
| FCF Conversion (FCF/Net Income) | 0.93x | 0.85x | 1.04x | 1.11x | 0.89x | 1.08x | 0.83x | 0.79x | 0.23x | 0.99x |
| Interest Paid | - | - | - | - | - | - | - | 84K | 0 | 0 |
| Taxes Paid | - | - | - | - | - | - | - | 0 | 0 | 0 |
CATX Key Ratios
Perspective Therapeutics, Inc. (CATX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -45.64% | -85.72% | -76.32% | -48.78% | -34.47% | -18.54% | -24.65% | -71.65% | -43.34% | -42.77% |
| Return on Invested Capital (ROIC) | -86.54% | -142.16% | -165.49% | -77.94% | -61.22% | -126.36% | -59.4% | -60.12% | 5.2% | 5.2% |
| Gross Margin | 17.6% | 31.1% | 41.66% | 52.93% | 50.94% | 42.76% | 23% | 100% | - | -150.17% |
| Net Margin | -129.43% | -113.12% | -66.31% | -33.77% | -31.71% | -66.26% | -206.5% | -3243.24% | - | -19728.65% |
| Debt / Equity | - | - | - | 0.18x | 0.07x | 0.01x | - | 0.03x | 0.01x | 0.01x |
| Interest Coverage | - | - | - | - | - | -62.11x | - | -487.39x | - | -948.77x |
| FCF Conversion | 0.93x | 0.85x | 1.04x | 1.11x | 0.89x | 1.08x | 0.83x | 0.79x | 0.23x | 0.99x |
| Revenue Growth | -0.17% | 24.41% | 23.48% | 32.35% | 3.85% | 7.38% | -34.19% | -79.81% | -100% | -74.35% |
CATX SEC Filings & Documents
Perspective Therapeutics, Inc. (CATX) SEC filings — annual & quarterly reports (10-K, 10-Q)
CATX Frequently Asked Questions
Perspective Therapeutics, Inc. (CATX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Perspective Therapeutics, Inc. (CATX) reported $0.6M in revenue for fiscal year 2024. This represents a 93% decrease from $7.8M in 1995.
Perspective Therapeutics, Inc. (CATX) saw revenue decline by 100.0% over the past year.
Perspective Therapeutics, Inc. (CATX) reported a net loss of $113.6M for fiscal year 2024.
Dividend & Returns
Perspective Therapeutics, Inc. (CATX) has a return on equity (ROE) of -43.3%. Negative ROE indicates the company is unprofitable.
Perspective Therapeutics, Inc. (CATX) had negative free cash flow of $112.4M in fiscal year 2024, likely due to heavy capital investments.
Explore More CATX
Perspective Therapeutics, Inc. (CATX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates